Tresiba Medicare Part D Coverage: What Women Need to Know About Insulin Degludec Access

Does Medicare Part D Cover Tresiba?

Most Medicare Part D plans do cover Tresiba, but coverage is not guaranteed on every formulary and the tier placement matters a great deal for what you pay. The Inflation Reduction Act capped out-of-pocket cost for covered insulins, including Tresiba, at $35 per month per insulin for Medicare beneficiaries starting in 2023. That cap applies whether you are in the deductible phase, the coverage gap, or the catastrophic phase of your Part D benefit.

The $35 cap is meaningful, but it only applies if Tresiba is on your plan's formulary. If your plan excludes it entirely, you would need either a formulary exception or a switch to a covered alternative.

How to Check if Your Plan Covers Tresiba

Use the Medicare Plan Finder at Medicare.gov and enter the drug name "insulin degludec" or the brand name Tresiba. The tool shows every Part D plan in your zip code that covers the drug, the tier, and the estimated annual cost based on your usage.

Steps to follow:

• Go to Medicare.gov/plan-compare
• Enter your zip code and Medicare ID
• Add Tresiba to your drug list using the brand or generic name
• Compare plans by estimated annual drug cost, not just monthly premium
• Note which plans place it at Tier 2 (preferred brand) versus Tier 3 or Tier 4

Open Enrollment runs October 15 through December 7 each year. If you are already enrolled and your plan drops Tresiba mid-year, you may qualify for a Special Enrollment Period only in specific circumstances.

Requesting a Formulary Exception

If Tresiba is not on your plan's formulary, your prescriber can submit a formulary exception request showing that covered alternatives (such as insulin glargine U-100 or U-300) are medically inappropriate for you. For women with a documented history of nocturnal hypoglycemia, the flexible dosing window of insulin degludec, which BEGIN_STUDY_CITE allows dosing at any time of day with at least 8 hours between injections, is a clinically grounded reason to request an exception.

How Much Does Tresiba Cost Without Medicare or With a Gap in Coverage?

Cash-pay cost for Tresiba averages roughly $35 per fill at major pharmacy chains when you use a GoodRx-type coupon or discount card. Without any discount, the list price of one Tresiba FlexTouch pen (3 mL, 100 units/mL) runs considerably higher, often exceeding $300 per pen at retail.

Novo Nordisk Patient Assistance Programs

Novo Nordisk runs two programs that matter most:

Novo Nordisk Patient Assistance Program (PAP). For uninsured or underinsured patients who meet income thresholds (generally at or below 400% of the federal poverty level), Novo Nordisk provides Tresiba at no charge. Applications are submitted through NovoCare. Income documentation is required and approval takes two to four weeks on average.

My$99Insulin. Novo Nordisk offers a program under which eligible patients can obtain a 90-day supply of Tresiba for $99 regardless of insurance status. Visit the NovoCare My$99Insulin page to confirm current terms, because program eligibility rules change and you should verify directly before relying on this figure.

Manufacturer Coupon for Tresiba

For commercially insured patients (not Medicare or Medicaid), Novo Nordisk offers a savings card that can reduce monthly out-of-pocket cost to as low as $99 or less per month, depending on the current offer. Manufacturer coupons are not usable with Medicare. If you have Medicare as your primary insurer, the $35 insulin cap is the primary cost-reduction tool; savings cards are legally prohibited for use in that setting. Check NovoCare.com directly for the current commercial savings card terms.

Compounded Insulin Degludec

A small number of 503B outsourcing facilities compound insulin degludec for substantially lower cost, sometimes at $0 through affiliated assistance programs. Compounded insulin is not FDA-approved and is not substitutable for brand Tresiba in terms of regulatory equivalence. The FDA has noted concerns about compounded insulin safety and recommends using FDA-approved products when they are accessible. If cost is the only barrier, exhaust the manufacturer assistance and $35 Medicare cap options before turning to compounders.

Tresiba and Women's Health: Why Sex-Specific Physiology Matters for Your Dose

Menstrual Cycle and Insulin Sensitivity

Insulin resistance is not static in women with diabetes. It shifts across the menstrual cycle in a predictable pattern. In the follicular phase (days 1 through 14), estrogen tends to increase insulin sensitivity, which can lower your total daily insulin requirement. In the luteal phase (days 15 through 28), progesterone antagonizes insulin action, raising insulin requirements by an average of 10 to 26% in women with type 1 diabetes, according to data published in Diabetes Care. Tracking your glucose patterns against your cycle is not optional; it is how you prevent both luteal-phase hyperglycemia and follicular-phase hypoglycemia.

Tresiba's ultra-long action profile (half-life approximately 25 hours, steady state at 72 hours) means dose adjustments should be made no more frequently than every three to four days to avoid stacking. This matters during menstrual transitions: do not chase a two-day luteal-phase glucose rise with daily dose increases.

PCOS and Insulin Resistance

Polycystic ovary syndrome affects 6 to 12% of reproductive-age women in the United States and is the most common endocrine disorder in that age group. The underlying hyperinsulinemia in PCOS is driven by peripheral insulin resistance, and women with PCOS who develop type 2 diabetes may need higher basal insulin doses than would be expected from body weight alone. Women with PCOS and type 2 diabetes should have their basal insulin re-evaluated any time their menstrual pattern shifts significantly, because cycle regularity is a rough proxy for androgen-driven metabolic flux.

Perimenopause and Menopause

Estrogen decline during perimenopause changes insulin sensitivity in ways that are often underappreciated by clinicians. The Menopause Society notes that the metabolic shift at menopause increases visceral adiposity and worsens insulin resistance, which may increase basal insulin requirements even in women whose weight is stable. Women transitioning through perimenopause may see their previously stable Tresiba dose become insufficient without any change in diet or activity. Conversely, if menopausal hormone therapy (MHT) is started, estrogen replacement can improve insulin sensitivity and lower the required dose.

A practical framework for women managing Tresiba across life stages:

| Life Stage | Expected Insulin Sensitivity Direction | Tresiba Dose Implication | |---|---|---| | Follicular phase | Higher sensitivity | May need less basal | | Luteal phase | Lower sensitivity | May need 10-26% more basal | | Pregnancy (T1/T2) | Progressively decreasing through T2/T3 | Significant dose escalation often required | | Postpartum | Sharp drop in resistance | High hypoglycemia risk; reduce dose immediately | | Perimenopause | Decreasing sensitivity (variable) | May need gradual dose increase | | Post-menopause on MHT | Modest improvement in sensitivity | Re-evaluate dose after MHT initiation |

Pregnancy, Lactation, and Contraception

Pregnancy Safety

Tresiba carries an FDA Pregnancy Category B designation based on animal reproduction studies showing no harm to the fetus, but the human data are limited. The key EXPECT trial studied insulin degludec in pregnant women with type 1 diabetes and found rates of severe hypoglycemia and neonatal outcomes similar to insulin detemir, though the trial was not powered to detect small safety differences. ACOG recommends that women with pregestational diabetes maintain near-normal glycemic control throughout pregnancy to reduce the risk of congenital anomalies, preterm birth, macrosomia, and stillbirth.

Key pregnancy considerations with Tresiba:

• Insulin requirements typically increase by 50 to 100% or more during the second and third trimesters.
• Tresiba's very long half-life can make rapid dose adjustments more difficult compared with NPH or insulin detemir; discuss this with your endocrinologist before conception.
• Insulin glargine U-100 and insulin detemir have longer safety records in pregnancy. Switching to one of these during pregnancy is a reasonable clinical decision and should be made in partnership with your maternal-fetal medicine specialist.
• Uncontrolled diabetes in pregnancy carries substantially higher risk to the fetus than any theoretical insulin risk. Do not stop insulin without medical supervision.

If you are trying to conceive and currently use Tresiba, discuss the transition plan with your endocrinologist or OB-GYN at least three months before attempting pregnancy.

Lactation

Insulin is a large peptide molecule. It does not transfer to breast milk in clinically significant amounts, and any that does enter milk would be digested in the infant's gastrointestinal tract rather than absorbed systemically. LactMed classifies insulin as compatible with breastfeeding. You can continue Tresiba while breastfeeding.

One postpartum caution: breastfeeding itself lowers blood glucose and increases hypoglycemia risk in insulin-using women, particularly in the first six weeks postpartum when insulin sensitivity recovers rapidly. Keep fast-acting carbohydrates accessible during every feeding session.

Contraception Requirements

Tresiba is not a teratogen in the way that some non-insulin diabetes medications are. However, unplanned pregnancy in a woman with poorly controlled diabetes carries serious fetal risk. Women of reproductive age using Tresiba for type 1 or type 2 diabetes should use effective contraception unless actively trying to conceive, and should work with their care team to achieve glycated hemoglobin (HbA1c) below 6.5 to 7.0% before conception, per ACOG guidelines.

Who Tresiba Is Right For and Who Should Consider Alternatives

Women Who May Benefit Most from Tresiba

• Women with type 1 or type 2 diabetes who experience nocturnal hypoglycemia on insulin glargine, because Tresiba's flatter pharmacodynamic profile produces less peak effect and lower hypoglycemia risk in head-to-head trials.
• Women with irregular schedules (shift workers, new mothers, perimenopause-related insomnia disrupting routines) who cannot inject at the same time every day; Tresiba allows a flexible dosing window of 8 or more hours between doses.
• Women on Medicare for whom the $35 insulin cap makes Tresiba genuinely affordable.
• Women with PCOS and type 2 diabetes who have struggled with hypoglycemia on other basal insulins.

Women Who Should Discuss Alternatives

• Women planning pregnancy or currently pregnant: insulin detemir has a larger body of safety data in pregnancy and is often preferred.
• Women with Medicare plans that do not include Tresiba on their formulary and for whom a formulary exception is denied: insulin glargine biosimilars (Semglee, Rezvoglar) are on most formularies at lower tiers.
• Women with type 2 diabetes who are also candidates for GLP-1 receptor agonists: a GLP-1 plus a lower basal insulin dose may reduce overall insulin exposure and support weight management.

How to Switch from Another Basal Insulin to Tresiba

Switching from insulin glargine U-100 or insulin detemir to Tresiba is generally done at a unit-for-unit conversion, though many providers start at 80% of the prior total daily basal dose and titrate up to account for Tresiba's potency profile. The BEGIN trials program, the clinical development series for insulin degludec, used titration protocols targeting a fasting glucose of 70 to 90 mg/dL with dose increases of two units every three days.

For women switching at a luteal-phase time point, note that you may be starting at a period of naturally higher insulin resistance. Starting the switch during the follicular phase (days 1 to 7 of your cycle) when insulin sensitivity is higher may give you a cleaner baseline to titrate from. This is not established in clinical guidelines but is a practical consideration your provider may find useful.

Comparing Tresiba to Other Long-Acting Insulins on Cost and Coverage

| Insulin | Brand | Typical Part D Tier | $35 Cap Eligible | Notable Difference | |---|---|---|---|---| | Insulin degludec | Tresiba | Tier 3-4 | Yes | Flexible dosing window; lowest hypoglycemia rate in BEGIN trials | | Insulin glargine U-100 | Lantus, Basaglar | Tier 2-3 | Yes | Longest safety record including pregnancy | | Insulin glargine U-300 | Toujeo | Tier 3-4 | Yes | More concentrated; may suit women with higher total daily doses | | Insulin glargine (biosimilar) | Semglee, Rezvoglar | Tier 2 | Yes | Lower list price; often preferred tier | | Insulin detemir | Levemir | Tier 3 | Yes | Preferred in pregnancy by many specialists |

All listed insulins are subject to the $35 Medicare insulin cap under the Inflation Reduction Act. The formulary tier still determines whether your plan will fill the drug at all without a prior authorization.

Steps to Take Right Now if You Cannot Afford Tresiba

1. Verify your Medicare Part D formulary. Log into your plan's member portal or call the number on your insurance card. Ask specifically: "Is insulin degludec (Tresiba) on my formulary, and what tier?"

2. Invoke the $35 insulin cap. If Tresiba is on your formulary, pharmacists are required to apply the $35 cap. If you were charged more, you can request a retroactive adjustment or file a grievance through your plan.

3. Ask your prescriber for a prior authorization or formulary exception. Provide documentation of any hypoglycemia history or clinical reason Tresiba is preferred over alternatives. Formulary exception decisions must be made within 72 hours, or 24 hours for urgent cases, per CMS rules.

4. Apply to NovoCare. Visit novocare.com and complete the patient assistance application. Have your most recent tax return or income documentation ready.

5. Ask your pharmacist about GoodRx. For months when Medicare is not providing coverage (for instance, during a coverage gap before the $35 cap was fully implemented for your plan type), a GoodRx coupon can bring cash-pay cost to approximately $35 at major chains.

6. Contact the Medicare helpline. Call 1-800-MEDICARE (1-800-633-4227) to file a complaint if you believe you are being overcharged for a covered insulin.

Evidence Gaps Women Should Know About

Women have been underrepresented in most large insulin trials. The BEGIN trial series that established Tresiba's efficacy enrolled both men and women, but sex-stratified subgroup analyses were not the primary endpoint in most studies. Data specifically on Tresiba's pharmacokinetics in women across the menstrual cycle, in perimenopause, or on combined hormonal contraception are not available in the published literature as of early 2026. What is known about cycle-phase insulin sensitivity changes comes largely from studies of older insulin formulations.

The honest clinical position: cycle-phase dosing adjustments for Tresiba are extrapolated from physiological principles and from data on other basal insulins, not from Tresiba-specific randomized trials in women. Your own continuous glucose monitor (CGM) data is currently the best tool for personalizing your dose to your cycle.